AU2019240905B2 - HER3 antigen-binding molecules - Google Patents

HER3 antigen-binding molecules Download PDF

Info

Publication number
AU2019240905B2
AU2019240905B2 AU2019240905A AU2019240905A AU2019240905B2 AU 2019240905 B2 AU2019240905 B2 AU 2019240905B2 AU 2019240905 A AU2019240905 A AU 2019240905A AU 2019240905 A AU2019240905 A AU 2019240905A AU 2019240905 B2 AU2019240905 B2 AU 2019240905B2
Authority
AU
Australia
Prior art keywords
her3
amino acid
antigen
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019240905A
Other languages
English (en)
Other versions
AU2019240905A1 (en
Inventor
Jerome Douglas BOYD-KIRKUP
Siyu GUAN
Piers INGRAM
Konrad PASZKIEWICZ
Vicente SANCENON
Dipti THAKKAR
Zhihao WU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hummingbird Bioscience Holdings Ltd
Original Assignee
Hummingbird Bioscience Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hummingbird Bioscience Holdings Ltd filed Critical Hummingbird Bioscience Holdings Ltd
Publication of AU2019240905A1 publication Critical patent/AU2019240905A1/en
Assigned to Hummingbird Bioscience Holdings Limited reassignment Hummingbird Bioscience Holdings Limited Amend patent request/document other than specification (104) Assignors: HUMMINGBIRD BIOSCIENCE HOLDINGS PTE. LTD.
Assigned to Hummingbird Bioscience Pte. Ltd. reassignment Hummingbird Bioscience Pte. Ltd. Request for Assignment Assignors: Hummingbird Bioscience Holdings Limited
Application granted granted Critical
Publication of AU2019240905B2 publication Critical patent/AU2019240905B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
AU2019240905A 2018-03-29 2019-03-29 HER3 antigen-binding molecules Active AU2019240905B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2018/058259 WO2019185164A1 (fr) 2018-03-29 2018-03-29 Molécules de liaison à l'antigène her3
AUPCT/EP2018/058259 2018-03-29
US16/170,370 US20190300624A1 (en) 2018-03-29 2018-10-25 Her3 antigen-binding molecules
US16/170,370 2018-10-25
PCT/EP2019/058035 WO2019185878A1 (fr) 2018-03-29 2019-03-29 Molécules de liaison à l'antigène her3

Publications (2)

Publication Number Publication Date
AU2019240905A1 AU2019240905A1 (en) 2020-11-19
AU2019240905B2 true AU2019240905B2 (en) 2025-06-12

Family

ID=62027941

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019240905A Active AU2019240905B2 (en) 2018-03-29 2019-03-29 HER3 antigen-binding molecules

Country Status (14)

Country Link
US (6) US20190300624A1 (fr)
EP (2) EP3851458A1 (fr)
JP (3) JP7118331B2 (fr)
KR (2) KR102593409B1 (fr)
CN (2) CN114751983A (fr)
AU (1) AU2019240905B2 (fr)
CA (1) CA3094758A1 (fr)
DK (1) DK3645571T3 (fr)
ES (1) ES2864700T3 (fr)
PL (1) PL3645571T3 (fr)
PT (1) PT3645571T (fr)
SG (1) SG11202009361PA (fr)
TW (1) TWI825086B (fr)
WO (2) WO2019185164A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109476741B (zh) 2016-03-25 2023-02-24 拜奥穆尼克斯制药 与cd38和pd-l1结合的分子
CN109563166B (zh) * 2016-04-28 2022-12-20 拜奥穆尼克斯制药 靶向egfr和her2的双特异性抗体
CN120842423A (zh) 2017-03-27 2025-10-28 拜奥穆尼克斯制药 稳定的多特异性抗体
WO2019185164A1 (fr) * 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Molécules de liaison à l'antigène her3
GB201817354D0 (en) * 2018-10-25 2018-12-12 Hummingbird Bioscience Pte Ltd Engineered FC
GB201913079D0 (en) 2019-09-11 2019-10-23 Hummingbird Bioscience Holdings Pte Ltd Treatment and prevention of cancer using her3 antigen-binding molecules
CN111647074B (zh) * 2020-06-01 2023-12-19 皖南医学院 一种her3二聚化界面抗原肽、重组抗原肽、编码基因及其应用
CN112259251B (zh) * 2020-10-20 2021-07-13 昭衍(北京)医药科技有限公司 一种药代动力学参数简化分析方法及系统
US12551584B1 (en) 2020-12-07 2026-02-17 Actinium Pharmaceuticals, Inc. Lewis Y radioimmunotherapy for the treatment of cancer
US12297273B2 (en) * 2021-05-27 2025-05-13 Sanofi Fc variant with enhanced affinity to Fc receptors and improved thermal stability
GB202108449D0 (en) 2021-06-14 2021-07-28 Hummingbird Bioscience Holdings Pte Ltd Cells expressing her3 antigen-binding molecules
CA3227422A1 (fr) * 2021-07-26 2023-02-02 Kite Pharma, Inc. Recepteurs dnvsig3 et dnvsig8 et leurs procedes d'utilisation
CN118119719A (zh) 2021-08-13 2024-05-31 蜂鸟生物科技私人有限公司 使用her3抗原结合分子治疗和预防癌症
WO2024121163A1 (fr) 2022-12-06 2024-06-13 Cancer Research Technology Limited Combinaison de 10d1f et d'un inhibiteur des androgènes pour le traitement et la prévention de cancers
EP4630054A1 (fr) 2022-12-07 2025-10-15 Hummingbird Bioscience Pte. Ltd. Association pour traitement et prévention du cancer
PE20252676A1 (es) 2023-01-03 2025-11-24 Hummingbird Bioscience Pte Ltd Conjugado anticuerpo-farmaco que se une a her3
KR20260026009A (ko) 2023-04-06 2026-02-25 허밍버드 바이오사이언스 피티이. 엘티디. Her3 항원 결합 분자를 이용한 암의 치료 및 예방
KR20260022498A (ko) 2023-04-14 2026-02-19 허밍버드 바이오사이언스 피티이. 엘티디. 암의 치료 및 예방을 위한 조합물
WO2025056781A1 (fr) 2023-09-15 2025-03-20 Hummingbird Bioscience Pte. Ltd. Traitement et prévention du cancer à l'aide de molécules de liaison à her3

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013084148A2 (fr) * 2011-12-05 2013-06-13 Novartis Ag Anticorps pour le récepteur 3 du facteur de croissance épidermique (her3) dirigé contre le domaine ii de her3

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
EP1228766A1 (fr) 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Phosphorylation de PYK2 par HER3 induit l'invasion de tumeurs
US7744882B2 (en) 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 methods of detection and antibodies
SG178789A1 (en) * 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
AU2010242914B2 (en) 2009-04-29 2014-11-13 Trellis Bioscience, Llc Improved antibodies immunoreactive with heregulin-coupled HER3
CA2792327C (fr) 2010-03-11 2019-09-24 Merrimack Pharmaceuticals, Inc. Utilisation d'inhibiteurs d'erbb3 dans le traitement de cancers du sein triples negatifs et de type basal
CN102906118B (zh) * 2010-05-20 2017-07-28 埃博灵克斯股份有限公司 与her3相关的生物材料
NZ607337A (en) * 2010-08-20 2015-06-26 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
ITRM20100577A1 (it) * 2010-11-02 2012-05-03 Takis Srl Immunoterapia contro il recettore erbb-3
US20140134170A1 (en) 2011-03-11 2014-05-15 Merrimack Pharmaceuticals, Inc. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
KR102101806B1 (ko) 2011-05-19 2020-04-20 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-인간-her3 항체 및 이의 용도
HK1200468A1 (en) 2011-09-30 2015-08-07 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
US9725511B2 (en) 2012-11-08 2017-08-08 Hoffmann-La Roche Inc. Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4
MX2015005757A (es) 2012-11-08 2015-11-18 Hoffmann La Roche Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3.
US10221230B2 (en) 2013-02-25 2019-03-05 Ohio State Innovation Foundation HER-1, HER-3 and IGF-1R compositions and uses thereof
CN105143270B (zh) 2013-02-26 2019-11-12 罗切格利卡特公司 双特异性t细胞活化抗原结合分子
CN105209493B (zh) 2013-03-14 2019-05-03 德克萨斯州大学系统董事会 用于诊断和治疗用途的her3特异性单克隆抗体
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
WO2015048804A2 (fr) 2013-09-30 2015-04-02 Daiichi Sankyo Co., Ltd. Biomarqueurs protéiques et leurs utilisations
TW201601754A (zh) 2013-09-30 2016-01-16 第一三共股份有限公司 核酸生物標記及其用途
IL301147A (en) 2014-02-28 2023-05-01 Merus Nv An antibody that binds to ErbB-2 and ErbB-3
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
MX2016014862A (es) 2014-05-14 2017-02-27 Hoffmann La Roche Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2.
WO2016011167A1 (fr) 2014-07-16 2016-01-21 Dana-Farber Cancer Institute, Inc., Et Al Inhibition de her3 dans les cancers ovariens séreux à évolution lente
CN110642952B (zh) * 2014-08-14 2021-05-25 上海生物制品研究所有限责任公司 抗her3抗体、其制法及其应用
CA2959716A1 (fr) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anticorps anti-her3 et leurs utilisations
EP3191128A4 (fr) 2014-09-11 2018-03-14 Celldex Therapeutics, Inc. Utilisations d'anticorps anti-her3 pour le traitement du cancer
EP3283111A4 (fr) 2015-04-17 2019-04-17 Celldex Therapeutics, Inc. Biomarqueurs liés au traitement du cancer utilisant des inhibiteurs de her3 et egfr
TW201716439A (zh) 2015-07-20 2017-05-16 美國禮來大藥廠 Ｈｅｒ３抗體
WO2017214433A1 (fr) * 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinaisons de conjugués anticorps-médicament à base de pbd avec des d'inhibiteurs de flt3
CA3024359A1 (fr) * 2016-06-23 2017-12-28 Jiangsu Hengrui Medicine Co., Ltd. Anticorps anti-lag-3, fragment de celui-ci se liant a l'antigene, et son application pharmaceutique
WO2019185164A1 (fr) * 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Molécules de liaison à l'antigène her3
GB201913079D0 (en) 2019-09-11 2019-10-23 Hummingbird Bioscience Holdings Pte Ltd Treatment and prevention of cancer using her3 antigen-binding molecules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013084148A2 (fr) * 2011-12-05 2013-06-13 Novartis Ag Anticorps pour le récepteur 3 du facteur de croissance épidermique (her3) dirigé contre le domaine ii de her3

Also Published As

Publication number Publication date
SG11202009361PA (en) 2020-10-29
CN112513095A (zh) 2021-03-16
AU2019240905A1 (en) 2020-11-19
ES2864700T3 (es) 2021-10-14
JP7545437B2 (ja) 2024-09-04
KR102593409B1 (ko) 2023-10-26
JP2021510535A (ja) 2021-04-30
US20190300624A1 (en) 2019-10-03
TWI825086B (zh) 2023-12-11
EP3851458A1 (fr) 2021-07-21
US20210024651A1 (en) 2021-01-28
CN114751983A (zh) 2022-07-15
JP2022118731A (ja) 2022-08-15
DK3645571T3 (da) 2021-02-22
JP7118331B2 (ja) 2022-08-16
TW201942136A (zh) 2019-11-01
US20200308275A1 (en) 2020-10-01
PT3645571T (pt) 2021-03-24
JP2024164153A (ja) 2024-11-26
CN112513095B (zh) 2022-03-08
WO2019185164A1 (fr) 2019-10-03
US20250019461A1 (en) 2025-01-16
WO2019185878A1 (fr) 2019-10-03
CA3094758A1 (fr) 2019-10-03
KR20230148864A (ko) 2023-10-25
US20240092937A1 (en) 2024-03-21
KR20200139725A (ko) 2020-12-14
US10662241B1 (en) 2020-05-26
PL3645571T3 (pl) 2021-07-05
US11780933B2 (en) 2023-10-10
JP7825000B2 (ja) 2026-03-05
EP3645571B1 (fr) 2021-01-20
EP3645571A1 (fr) 2020-05-06

Similar Documents

Publication Publication Date Title
US11208498B2 (en) Treatment and prevention of cancer using HER3 antigen-binding molecules
US20250019461A1 (en) Her3 antigen-binding molecules
HK40026637A (en) Her3 antigen-binding molecules
HK40026637B (en) Her3 antigen-binding molecules
HK40075856A (en) Her3 antigen-binding molecules
HK40052624B (en) Treatment and prevention of cancer using her3 antigen-binding molecules

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: HUMMINGBIRD BIOSCIENCE HOLDINGS LIMITED

Free format text: FORMER NAME(S): HUMMINGBIRD BIOSCIENCE HOLDINGS PTE. LTD.

PC1 Assignment before grant (sect. 113)

Owner name: HUMMINGBIRD BIOSCIENCE PTE. LTD.

Free format text: FORMER APPLICANT(S): HUMMINGBIRD BIOSCIENCE HOLDINGS LIMITED

FGA Letters patent sealed or granted (standard patent)